Back to Search
Start Over
Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers.
- Source :
-
Journal of Antimicrobial Chemotherapy (JAC) . Jul2011, Vol. 66 Issue 7, p1567-1572. 6p. 4 Charts, 2 Graphs. - Publication Year :
- 2011
-
Abstract
- Objectives To evaluate the effect of pH-altering agents on S/GSK1349572 exposure in healthy subjects. Methods S/GSK1349572 is an unboosted, once-daily, next-generation HIV integrase inhibitor. In the first study, 16 subjects received four single-dose treatments: (i) S/GSK1349572 50 mg; (ii) S/GSK1349572 50 mg with a multivitamin (MVI; One A Day Maximum); (iii) S/GSK1349572 50 mg with a liquid antacid (Maalox Advanced Maximum Strength); and (iv) S/GSK1349572 50 mg 2 h before an antacid. In the second study, 12 subjects received a single dose of S/GSK1349572 alone and on day 5 of omeprazole. Results All treatments were well tolerated. MVI co-administration modestly decreased S/GSK1349572 AUC by 33%. Concurrent antacid co-administration reduced S/GSK1349572 AUC by 74% and staggered antacid dosing significantly diminished this interaction, with a reduction in S/GSK1349572 AUC of 26%. Omeprazole did not significantly affect S/GSK1349572 exposure. Conclusions S/GSK1349572 can be taken with proton pump inhibitors and MVIs without dose adjustment but should be administered 2 h before or 6 h after antacids. [ABSTRACT FROM PUBLISHER]
Details
- Language :
- English
- ISSN :
- 03057453
- Volume :
- 66
- Issue :
- 7
- Database :
- Academic Search Index
- Journal :
- Journal of Antimicrobial Chemotherapy (JAC)
- Publication Type :
- Academic Journal
- Accession number :
- 61387664
- Full Text :
- https://doi.org/10.1093/jac/dkr139